Background The efficacy of salbutamol-ipratropium bromide
agonists are potent bronchodilators, but multiple or large doses may cause adrenergic side effects.
bronchodilator with a slower onset, longer duration of action, and less adrenergic side effects compared to those of beta 2 -agonists. have shown that a combination of salbutamol and improve lung function and clinical score, while lowering emergency department (ED) admission duration and hospital admission rates. 8, 9 Other studies have also reported salbutamol-ipratropium bromide while studies on its use in patients with mild asthma nebulization has commonly been given to patients one Indonesian study to date has been published on this subject.
ipratropium nebulization with salbutamol alone in pediatric patients with mild to moderate asthma and hospital admission rates of the two groups.
Methods
This study was designed as a single-blind, randomized, compared the effects of nebulization with salbutamolipratropium combination to those of salbutamol alone. 9 were signs of respiratory failure, need of intensive care management, heart abnormality, pneumonia or other respiratory disorders altering lung function, ocular disorder altering intraocular pressure or pupillar resaltering intraocular pressure or pupillar response examination), hypersensitivity to ipratropium or salbutamol, and those who had received ipratropium consent.
either salbutamol-ipratropium bromide (experimental group) or salbutamol alone (control group), according to their allocated group. minute interval between treatments. The duration including demographic characteristics (age, sex, and nutritional status), asthma history, treatment history, asthma comorbidities (allergic rhinitis or sinusitis), duration of current symptoms, and asthma severity.
saturation by pulse oxymetry (Oxy3, OneMed). until 2 hours post-nebulization, including the same parameters measured at baseline. For patients with was measured by forced expiration maneuver (patient twice performed forced expiration after maximal inspiration with at least a 5-second interval between forced expiration). Only the best value was recorded. hours post-treatment were admitted to the hospital. clinical score at baseline was measured by a research group random allocation instructions. By the time the arrived at the ED to continue data measurements.
Individual severity scores were summed and divided Table 1 ). Interrater reliability was measured
The primary outcome was nebulization efficacy, measured by several parameters including decreased saturation, decreased respiratory rate, and decreased from baseline. The proportion of patients with after treatment, and side effects of medications. a formula of mean difference of two independent groups, with previous study showed that the standard deviation of mean change in clinical asthma score between the salbutamol-ipratropium and salbutamol groups was 9 the clinically significant difference was set at of 32 patients, were needed for this study.
saturation, and respiratory rates between groups were if the data had an abnormal distribution. Differences in This study was approved by The Medical Research Ethics Committee, Faculty of Medicine, University of Indonesia.
Results
had received ipratropium bromide within the prior were allocated to each group). All baseline parameters were similar between the two groups ( Table 2) .
clinical scores decreased more in the experimental group, but they were not statistically or clinically (Table 3 we found an apparent difference in the mean decrease of difference between the two groups seemed substantial, but statistical significance could not be established Table 3 ).
experimental group than in the control group. The was abnormally distributed) ( Table 4   Table 4 ).
observation, but statistical analysis could not be performed (Table 4) . minutes, there were similarly no significant differences Table  5 was also no difference between groups (Table 5) , while reversibility tended to be higher in the experimental group, but the sample size was too small to analyze (Table 5) .
Before intervention, all subjects had oxygen needed. There were no differences in oxygen saturation difference in the decrease of respiratory rates between the two groups ( Table 6 in respiratory rates in the experimental group. These Table 6 ) but statistical subjects were given ipratropium bromide nebulization and intravenous steroids. They were analyzed in the control group, since we used intention-to-treat analyses. The number of hospital admissions was ( Table 7) . agreed to arterial puncture after the intervention, and the second patient agreed before the intervention. In both subjects, we found decreased pressure of 2 3 respectively) 2 and oxygen saturation were still normal. dryness to be of similar proportions in both groups. The unilateral decrease of light pupillar response was
The proportion of subjects with tachycardia was groups. Tachycardia resolved with time.
Discussion
This study had some limitations. In this single-blinded study, investigators were not blinded, but subjects were. Ideally, the study should be double-blinded, since we used a subjective parameter of efficacy (clinical score). saturation, respiratory rate, and proportion of hospital et al.
unless otherwise clinically indicated.
In our study, interrater reliability could only be
The same clinical score was used by previous studies that of our study.
subjects, but at the end of the study, we had more subanalysis could only be performed on subjects with while trying to demonstrate clinical differences in patients at our public facilities may be due to increasing numbers of private health centers with nebulization facilities as well as better maintenance treatment for asthma patients. Many previous studies on subjects with moderate rates in the ipratropium bromide group. The difference in admission rates between groups was greatest in in the experimental group), but it was not statistically Furthermore, our sample size was too small to detect any differences in hospitalization rates.
decreasing carbon dioxide levels. If the obstruction continues, the ventilation-perfusion mismatch can no longer be overcome by hyperventilation, thus resulting in hypoxemia and hypercapnia.
Carruthers et al. reported that the respiratory failure rate was only 4.2% among patients with oxygen saturation hypocapnia and normal oxygen saturation, consistent with previous studies.
The relatively low value 3 revealed a tendency towards metabolic acidosis which can be caused by the increase of plasma lactate due to increased respiratory muscle activity under hypoxic conditions. Beta2-agonist receptor stimulation may also generate gluconeogenesis, glycolyis and lipolysis, producing lactate. 23 The two not show clinical signs of metabolic acidosis, despite 3 , thus they did not need any additional specific management.
There were 2 patients with pupil abnormalities in the experimental group. These side effects were reversible. Mouth mucosal dryness did not differ between the groups. Tachycardia was also similar between the groups, and resolved with time. Tachycardia was not only due to side effects of medications, but was also a physiologic response to mismatched ventilation-perfusion, resolving as clinical condition improved. Qureshi et al., 8 Ducharme et al., and Rodrigo et al. also reported no significant differences in side effects with the addition of ipratropium bromide.Despite the study limitations, we conclude that salbutamol-ipratopium bromide nebulization showed better efficacy compared to salbutamol alone in patients with mild to moderate parameters of efficacy (clinical scores, oxygen saturation, respiratory rates, and hospital admission rates) were not different between groups. In subjects to better efficacy with the addition of ipratropium rate. Nevertheless, further studies with a larger necessary. 
